Hemangiopericytoma

Auguste, Louis‐Joseph; Razack, Mohamed S.; Sako, Kumao

doi:10.1002/jso.2930200416

Cited by 44 publications

(40 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our 5-and 10-year disease-specific survivals were 89 and 73%, respectively. Historically, hemangiopericytomas have been reported to have a worse prognosis than solitary fibrous tumor, with 5-and 10-year hemangiopericytoma survival rates as low as 59 and 47-70%, respectively, 3,15 and up to 48% disease-specific mortality. 16 In pleural solitary fibrous tumor, recurrence and mortality are reportedly predicted by both histology and resectability; typically, benign pedunculated tumors excised with clear margins have a recurrence rate of 2%, while sessile malignant solitary fibrous tumors may recur up to 63% of the time, resulting in a 30% mortality rate.…”

Section: Discussionmentioning

confidence: 99%

Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model

et al. 2012

View full text Add to dashboard Cite

Solitary fibrous tumor represents a spectrum of mesenchymal tumors, encompassing tumors previously termed hemangiopericytoma, which are classified as having intermediate biological potential (rarely metastasizing) in the 2002 World Health Organization classification scheme. Few series have reported on clinicopathological predictors with outcome data and formal statistical analysis in a large series of primary tumors as a single unified entity. Institutional pathology records were reviewed to identify primary solitary fibrous tumor cases, and histological sections and clinical records reviewed for canonical prognostic indicators, including patient age, tumor size, mitotic index, tumor cellularity, nuclear pleomorphism, and tumor necrosis. Patients (n ¼ 103) with resected primary solitary fibrous tumor were identified (excluding meningeal tumors). The most common sites of occurrence were abdomen and pleura; these tumors were larger than those occurring in the extremities, head and neck or trunk, but did not demonstrate significant outcome differences. Overall 5-and 10-year metastasis-free rates were 74 and 55%, respectively, while 5-and 10-year disease-specific survival rates were 89 and 73%. Patient age, tumor size, and mitotic index predicted both time to metastasis and disease-specific mortality, while necrosis predicted metastasis only. A risk stratification model based on age, size, and mitotic index clearly delineated patients at high risk for poor outcomes. While small tumors with low mitotic rates are highly unlikely to metastasize, large tumors Z15 cm, which occur in patients Z55 years, with mitotic figures Z4/10 high-power fields require close follow-up and have a high risk of both metastasis and death.

show abstract

Section: Discussionmentioning

confidence: 99%

Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In an evaluation of 60 patients, McMaster et al 18 found that 48% had died of disease. Of the19 patients reported by Auguste et al, 19 53% developed pulmonary metastases; the overall survivals were 59% and 47% at 5 and 10 years, respectively. Such a wide spread in reported outcome suggests a lack of uniform pathologic criteria in these studies.…”

Section: Discussionmentioning

confidence: 82%

“…These are clearly divergent survival data as compared to those previously reported. 4,18,19 We believe that this substantial difference in survival is due to our use of immunohistochemistry and electron microscopy in a multimodal pathologic review to exclude other soft tissue tumors histologically mimicking conventional HPC. The vastly different experience of improved overall survival for this cohort as compared to the literature is an important observation.…”

Section: Discussionmentioning

confidence: 99%

Conventional hemangiopericytoma

Espat

Lewis

Leung

et al. 2002

Cancer

183

View full text Add to dashboard Cite

BACKGROUNDHemangiopericytoma (HPC) is a rare vascular tumor, and pathologic distinction from synovial sarcoma and solitary fibrous tumor is a significant problem due to shared histologic features. In the current report the authors defined the clinical behavior and prognosis for patients with HPC.METHODSBetween July 1982 and February 1998, 62 patients with a diagnosis of primary, recurrent, or metastatic HPC were identified from a prospectively maintained database. The pathology of all cases for which material was available (57 cases) was re‐reviewed for histologic confirmation of the HPC diagnosis. Using strict pathologic criteria, including immunohistochemistry and electron microscopy, tumors from 25 of 57 patients qualified for the diagnosis of conventional hemangiopericytoma; those tumors formed the basis of the current report. Survival was determined by the Kaplan‐Meier method.RESULTSAt the time of initial presentation, 19 patients had primary tumors, 3 had locally recurrent disease, and 3 had metastatic disease. The most frequent anatomic sites for HPC were the extremities, the pelvis, and the head and neck, accounting for 80% of the total cases. The median followup (n = 25) was 49 months (range, 1 to 160 months). The two and five year overall survival rates (n = 25) were 93% and 86% respectively. The disease‐specific survival was 86% at last followup. Patients undergoing complete resection (n = 16) showed a 100% median survival at 60 months.CONCLUSIONSAt present, complete tumor resection for patients with conventional HPC is recommended. However, considering the favorable outcome in this disease, the authors caution against performing operations that may potentially cause loss of function or are limb threatening. Cancer 2002;95:1746–51. © 2002 American Cancer Society.DOI 10.1002/cncr.10867

show abstract

“…Because of its vascular ity and, when large enough in the pelvis or retroperitoneal space, it Hemangiopericytoma may occur anywhere that capillaries are found, although the most common sites are the lower extremities and pelvis. There is an equal male-to-female ratio and it can occur at any age [6,[11][12][13]15]. The most common clinical presentation of this rare tumor is a painless expanding mass.…”

Section: Discussionmentioning

confidence: 99%